Scholar Rock Holding Corporation (SRRK)


+0.05 (+0.79%)
Symbol SRRK
Price $6.36
Beta 0.841
Volume Avg. 0.40M
Market Cap 357.638M
Shares () -
52 Week Range 5.56-13.0
1y Target Est -
DCF Unlevered SRRK DCF ->
DCF Levered SRRK LDCF ->
ROE -63.77% Strong Sell
ROA -55.10% Strong Sell
Operating Margin -
Debt / Equity 32.30% Neutral
P/E -3.66 Strong Sell
P/B 2.52 Strong Buy


Consensus EPS

Upgrades & Downgrades

Latest SRRK news

Dr. Jay T. Backstrom M.D., M.P.H.
NASDAQ Global Select

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.